Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01372202 · ClinicalTrials.gov registry record · Phase 2
CHFR Methylation Status Esophageal Cancer Study
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01372202 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 31 participants.
The verdict
NCT01372202, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a Phase 2 Study of Paclitaxel with Cisplatin versus Fluoropyrimidine with a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies.
Interventions
- DRUG Cisplatin
- DRUG Oxaliplatin
- DRUG Paclitaxel
- RADIATION Radiotherapy
- DRUG 5-Fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01372202
The ClinicalTrials.gov registry entry for NCT01372202 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT01372202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01372202 about?
NCT01372202 is a clinical study titled "CHFR Methylation Status Esophageal Cancer Study". This is a Phase 2 Study of Paclitaxel with Cisplatin versus Fluoropyrimidine with a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies.
What is the current status of trial NCT01372202?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2011-06. Estimated completion is 2014-10-01.
What interventions are being tested in trial NCT01372202?
The interventions under investigation include: Cisplatin (DRUG), Oxaliplatin (DRUG), Paclitaxel (DRUG), Radiotherapy (RADIATION), 5-Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT01372202?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.